ArticleCureus2025
Heart Failure in Polycystic Ovarian Syndrome and Hypothyroidism: A Retrospective Large Database Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Polycystic ovarian syndrome (PCOS) carries similar risks to metabolic syndromes, and the population with hypothyroidism and concurrent PCOS may demonstrate exponential cardiovascular risk. There is a paucity of data on the cardiovascular outcomes of the population with PCOS. We aimed to address this gap. Methods We queried the National Inpatient Sample Database (2016-2020), selected the population with a diagnosis of PCOS, and stratified them according to the presence or absence of hypothyroidism. Multivariable logistic regression models were applied to predict the outcomes. The primary outcome was mortality, while secondary outcomes were heart failure (HF), type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), stroke, hypertension (HTN), hyperlipidemia (HLD), and deep venous thrombosis (DVT). Results There were 78,470 hospitalizations with PCOS, and 14.6% (11,455) had hypothyroidism (36.3 years ± 10). Compared to the non-hypothyroid group, the population with hypothyroidism did not differ in terms of mortality (OR: 0.9; 95% CI: 0.6-1.4), HTN (OR: 1.04; 95% CI: 0.9-1.09), stroke (OR: 1.1; 95% CI: 0.8-1.4), or DVT (OR: 0.9; 95% CI: 0.7-1.3) (p > 0.05 for each). However, they had a higher likelihood of HF (OR: 1.2; 95% CI: 1.04-1.4), CKD (OR: 1.2; 95% CI: 1.02-1.3), T2DM (OR: 1.2; 95% CI: 1.1-1.3), and HLD (OR: 1.2; 95% CI: 1.2-1.3) (p < 0.05 for each). Conclusion Among the population with PCOS, those with concurrent hypothyroidism had a higher association with HF, CKD, T2DM, and HLD. Risk stratification, prompt screening, close follow-up, and management may improve outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.